XML Print

Abstract:   (124 Views)
Background: Recently, the therapeutic and antioxidant effects of simvastatin on 7,12-dimethylbenz[a] anthracene (DMBA) induced breast cancer have been studied. To gain further understanding of the molecular mechanisms of simvastatin, this study investigated its effects on the expression of c-myc, cyclin D1 and p53 in normal mammary glands and tumors.
Methods: Female albino mice were divided into two groups; 1) N group: healthy mice without DMBA and 2) D group: mice with DMBA administration. After the appearance of tumors, D group mice are subdivided into 3 groups, as control (C), simvastatin- treated group (S), which received 80 mg/kg/day, orally and tamoxifen-treated group (T) with 50 mg/kg/day, orally. After 4 weeks, animals were sacrificed. Also, the tumors and normal mammary glands were removed for histopathological evaluations and analysis of gene expression by Real-Time Reverse Transcription Polymerase Chain Reaction.
Results: The results showed the up-regulation of c-myc and cyclin D1 in tumors of the control group compared with mammary glands of the N group. Similar to tamoxifen, the simvastatin treatment could normalize the expression of c-myc and cyclin D1. But the expression of p53 did not change in the treated groups.
Conclusions: Down-regulation of c-myc and cyclin D1 in treated tumors with simvastatin could be a possible molecular mechanism for its therapeutic effects in DMBA-induced breast cancer in mice.
Keywords: Breast cancer, Simvastatin, cyclin D1, c-myc, p53
Types of Manuscript: Original Research | Subject: Cellular and Molecular BioMedicine